A new era for fibrodysplasia ossificans progressiva: A druggable target for the second skeleton

Frederick S. Kaplan, David L. Glaser, Robert Pignolo, Eileen M. Shore

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a disabling genetic condition that leads to the formation of a second (heterotopic) skeleton, and is the most catastrophic disorder of heterotopic ossification in humans. Throughout childhood and early adult life, FOP progressively immobilizes all of the joints of the normotopic skeleton, rendering movement impossible. At present, there is no effective prevention or treatment. Recently, a recurrent mutation in the glycine-serine activation domain of the activin receptor 1A/activin-like kinase-2, a bone morphogenetic protein type I receptor, was reported in all sporadic and familial cases of classic FOP, making this one of the most highly specific disease-causing mutations in the human genome. The discovery of the FOP gene establishes a critical milestone in understanding FOP, reveals a highly conserved druggable target in the TGF-β/bone morphogenetic protein signaling pathway and compels therapeutic approaches for the development of small molecule signal transduction inhibitors for activin-like kinase-2. Effective therapies for FOP, and possibly for a vast array of more common conditions of heterotopic ossification, will be based on blocking activin-like kinase-2, a critical node in the BMP signaling pathway.

Original languageEnglish (US)
Pages (from-to)705-712
Number of pages8
JournalExpert Opinion on Biological Therapy
Volume7
Issue number5
DOIs
StatePublished - May 1 2007
Externally publishedYes

Fingerprint

Myositis Ossificans
Activins
Skeleton
Phosphotransferases
Type I Bone Morphogenetic Protein Receptors
Genes
Activin Receptors
Heterotopic Ossification
Signal transduction
Bone Morphogenetic Proteins
Glycine
Serine
Chemical activation
Mutation
Molecules
Human Genome
Signal Transduction
Joints
Therapeutics

Keywords

  • Activin receptor IA
  • Activin-like kinase-2
  • Activin-like kinases
  • Bone morphogenetic protein
  • Bone morphogenetic protein receptors
  • Fibrodysplasia ossificans progressiva
  • Heterotopic ossification
  • Metamorphosis
  • Small molecule signal transduction inhibitor

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

A new era for fibrodysplasia ossificans progressiva : A druggable target for the second skeleton. / Kaplan, Frederick S.; Glaser, David L.; Pignolo, Robert; Shore, Eileen M.

In: Expert Opinion on Biological Therapy, Vol. 7, No. 5, 01.05.2007, p. 705-712.

Research output: Contribution to journalReview article

Kaplan, Frederick S. ; Glaser, David L. ; Pignolo, Robert ; Shore, Eileen M. / A new era for fibrodysplasia ossificans progressiva : A druggable target for the second skeleton. In: Expert Opinion on Biological Therapy. 2007 ; Vol. 7, No. 5. pp. 705-712.
@article{540c8fcdbb59431095a0472d78cab2f4,
title = "A new era for fibrodysplasia ossificans progressiva: A druggable target for the second skeleton",
abstract = "Fibrodysplasia ossificans progressiva (FOP) is a disabling genetic condition that leads to the formation of a second (heterotopic) skeleton, and is the most catastrophic disorder of heterotopic ossification in humans. Throughout childhood and early adult life, FOP progressively immobilizes all of the joints of the normotopic skeleton, rendering movement impossible. At present, there is no effective prevention or treatment. Recently, a recurrent mutation in the glycine-serine activation domain of the activin receptor 1A/activin-like kinase-2, a bone morphogenetic protein type I receptor, was reported in all sporadic and familial cases of classic FOP, making this one of the most highly specific disease-causing mutations in the human genome. The discovery of the FOP gene establishes a critical milestone in understanding FOP, reveals a highly conserved druggable target in the TGF-β/bone morphogenetic protein signaling pathway and compels therapeutic approaches for the development of small molecule signal transduction inhibitors for activin-like kinase-2. Effective therapies for FOP, and possibly for a vast array of more common conditions of heterotopic ossification, will be based on blocking activin-like kinase-2, a critical node in the BMP signaling pathway.",
keywords = "Activin receptor IA, Activin-like kinase-2, Activin-like kinases, Bone morphogenetic protein, Bone morphogenetic protein receptors, Fibrodysplasia ossificans progressiva, Heterotopic ossification, Metamorphosis, Small molecule signal transduction inhibitor",
author = "Kaplan, {Frederick S.} and Glaser, {David L.} and Robert Pignolo and Shore, {Eileen M.}",
year = "2007",
month = "5",
day = "1",
doi = "10.1517/14712598.7.5.705",
language = "English (US)",
volume = "7",
pages = "705--712",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - A new era for fibrodysplasia ossificans progressiva

T2 - A druggable target for the second skeleton

AU - Kaplan, Frederick S.

AU - Glaser, David L.

AU - Pignolo, Robert

AU - Shore, Eileen M.

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Fibrodysplasia ossificans progressiva (FOP) is a disabling genetic condition that leads to the formation of a second (heterotopic) skeleton, and is the most catastrophic disorder of heterotopic ossification in humans. Throughout childhood and early adult life, FOP progressively immobilizes all of the joints of the normotopic skeleton, rendering movement impossible. At present, there is no effective prevention or treatment. Recently, a recurrent mutation in the glycine-serine activation domain of the activin receptor 1A/activin-like kinase-2, a bone morphogenetic protein type I receptor, was reported in all sporadic and familial cases of classic FOP, making this one of the most highly specific disease-causing mutations in the human genome. The discovery of the FOP gene establishes a critical milestone in understanding FOP, reveals a highly conserved druggable target in the TGF-β/bone morphogenetic protein signaling pathway and compels therapeutic approaches for the development of small molecule signal transduction inhibitors for activin-like kinase-2. Effective therapies for FOP, and possibly for a vast array of more common conditions of heterotopic ossification, will be based on blocking activin-like kinase-2, a critical node in the BMP signaling pathway.

AB - Fibrodysplasia ossificans progressiva (FOP) is a disabling genetic condition that leads to the formation of a second (heterotopic) skeleton, and is the most catastrophic disorder of heterotopic ossification in humans. Throughout childhood and early adult life, FOP progressively immobilizes all of the joints of the normotopic skeleton, rendering movement impossible. At present, there is no effective prevention or treatment. Recently, a recurrent mutation in the glycine-serine activation domain of the activin receptor 1A/activin-like kinase-2, a bone morphogenetic protein type I receptor, was reported in all sporadic and familial cases of classic FOP, making this one of the most highly specific disease-causing mutations in the human genome. The discovery of the FOP gene establishes a critical milestone in understanding FOP, reveals a highly conserved druggable target in the TGF-β/bone morphogenetic protein signaling pathway and compels therapeutic approaches for the development of small molecule signal transduction inhibitors for activin-like kinase-2. Effective therapies for FOP, and possibly for a vast array of more common conditions of heterotopic ossification, will be based on blocking activin-like kinase-2, a critical node in the BMP signaling pathway.

KW - Activin receptor IA

KW - Activin-like kinase-2

KW - Activin-like kinases

KW - Bone morphogenetic protein

KW - Bone morphogenetic protein receptors

KW - Fibrodysplasia ossificans progressiva

KW - Heterotopic ossification

KW - Metamorphosis

KW - Small molecule signal transduction inhibitor

UR - http://www.scopus.com/inward/record.url?scp=34248223174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248223174&partnerID=8YFLogxK

U2 - 10.1517/14712598.7.5.705

DO - 10.1517/14712598.7.5.705

M3 - Review article

C2 - 17477807

AN - SCOPUS:34248223174

VL - 7

SP - 705

EP - 712

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 5

ER -